REGENXBIO Dirección
Dirección controles de criterios 2/4
El CEO de REGENXBIO es Curran Simpson , nombrado en Jul 2024, tiene una permanencia de menos de un año. compensación anual total es $2.95M, compuesta por 17.4% salario y 82.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.031% de las acciones de la empresa, por valor de $147.29K. La antigüedad media del equipo directivo y de la junta directiva es de 5.9 años y 7.4 años, respectivamente.
Información clave
Curran Simpson
Chief Executive Officer (CEO)
US$3.0m
Compensación total
| Porcentaje del salario del CEO | 17.4% |
| Permanencia del CEO | less than a year |
| Participación del CEO | 0.03% |
| Permanencia media de la dirección | 5.9yrs |
| Promedio de permanencia en la Junta Directiva | 7.4yrs |
Actualizaciones recientes de la dirección
Recent updates
REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track
Oct 31Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?
Sep 12
Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder
Aug 06REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 04Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price
Jul 26Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy
Jun 11REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
May 11REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
Apr 25Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
Mar 11Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers
Mar 07Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified
Mar 05Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 02Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips
Jan 19There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues
Dec 21We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully
Nov 09Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?
Aug 08REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%
May 11Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation
May 08Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be
Mar 05Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$239m |
| Jun 30 2024 | n/a | n/a | -US$241m |
| Mar 31 2024 | n/a | n/a | -US$260m |
| Dec 31 2023 | US$3m | US$513k | -US$263m |
| Sep 30 2023 | n/a | n/a | -US$261m |
| Jun 30 2023 | n/a | n/a | -US$274m |
| Mar 31 2023 | n/a | n/a | -US$270m |
| Dec 31 2022 | US$2m | US$475k | -US$280m |
| Sep 30 2022 | n/a | n/a | US$74m |
| Jun 30 2022 | n/a | n/a | US$91m |
| Mar 31 2022 | n/a | n/a | US$101m |
| Dec 31 2021 | US$3m | US$448k | US$128m |
| Sep 30 2021 | n/a | n/a | -US$212m |
| Jun 30 2021 | n/a | n/a | -US$145m |
| Mar 31 2021 | n/a | n/a | -US$121m |
| Dec 31 2020 | US$2m | US$428k | -US$111m |
| Sep 30 2020 | n/a | n/a | -US$91m |
| Jun 30 2020 | n/a | n/a | -US$135m |
| Mar 31 2020 | n/a | n/a | -US$103m |
| Dec 31 2019 | US$2m | US$382k | -US$95m |
| Sep 30 2019 | n/a | n/a | -US$64m |
| Jun 30 2019 | n/a | n/a | -US$49m |
| Mar 31 2019 | n/a | n/a | -US$37m |
| Dec 31 2018 | US$2m | US$371k | US$100m |
| Sep 30 2018 | n/a | n/a | US$80m |
| Jun 30 2018 | n/a | n/a | US$78m |
| Mar 31 2018 | n/a | n/a | US$53m |
| Dec 31 2017 | US$912k | US$361k | -US$73m |
Compensación vs. Mercado: La compensación total de Curran($USD2.95M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.16M).
Compensación vs. Ingresos: La compensación de Curran ha aumentado mientras la empresa no es rentable.
CEO
Curran Simpson (62 yo)
less than a year
Permanencia
US$2,950,002
Compensación
Mr. Curran M. Simpson, M.S., had been the Chief Operating Officer at REGENXBIO Inc. since January 2023 until July 01, 2024 and served as its Executive Vice President until July 01, 2024 and serves as its P...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | less than a year | US$2.95m | 0.031% $ 147.3k | |
| Executive VP & Chief Scientific Officer | 7.7yrs | US$2.99m | 0.061% $ 288.2k | |
| Advisor | less than a year | US$2.62m | 0.38% $ 1.8m | |
| Executive VP & Chief Medical Officer | 5.6yrs | US$3.31m | 0% $ 0 | |
| Executive VP & CFO | less than a year | sin datos | sin datos | |
| Executive VP & Chief Legal Officer | 8.3yrs | US$3.44m | 0.046% $ 218.6k | |
| Chief Communications & People Officer | 7.1yrs | sin datos | sin datos | |
| Executive VP of Commercial Strategy & Operations | 6.3yrs | sin datos | sin datos |
5.9yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de RGNX es experimentado (5.9 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | less than a year | US$2.95m | 0.031% $ 147.3k | |
| Independent Director | 9.1yrs | US$339.98k | 0.0061% $ 28.9k | |
| Independent Director | 3.2yrs | US$339.98k | 0.0061% $ 28.9k | |
| Independent Director | 9.5yrs | US$352.48k | 0.013% $ 62.3k | |
| Member of Scientific Advisor | no data | sin datos | sin datos | |
| Director | 15.8yrs | US$354.98k | 6.39% $ 30.3m | |
| Member of Scientific Advisor | no data | sin datos | sin datos | |
| Independent Director | 6.5yrs | US$327.48k | 0.0061% $ 28.9k | |
| Lead Independent Director | 8.3yrs | US$334.98k | 0.0061% $ 28.9k | |
| Independent Director | 3.2yrs | US$324.98k | 0.0061% $ 28.9k | |
| Chairman | 15.7yrs | US$5.92m | 0.63% $ 3.0m | |
| Independent Director | 2.4yrs | US$329.98k | 0.0040% $ 19.2k |
7.4yrs
Permanencia media
69.5yo
Promedio de edad
Junta con experiencia: La junta directiva de RGNX se considera experimentada (7.4 años de antigüedad promedio).